CordenPharma announces expansion of lipid excipients supply for coronavirus vaccine scale up.
CordenPharma announced on May 28, 2020 an amendment to an existing manufacturing agreement with Moderna, Inc. that enables CordenPharma to manufacture large-scale volumes of Moderna’s lipid excipients to be used in the manufacture of Moderna’s vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2).
The agreement expands a lipids manufacturing agreement originally signed in 2016 between Moderna and CordenPharma Switzerland to include CordenPharma Chenôve (France) and CordenPharma Colorado. The agreement will begin immediately to meet Moderna’s increasing demand to scale manufacturing of their vaccine candidate.
Source: CordenPharma
British Patient Capital Invests £10 Million in Maxion Therapeutics, Part of Series A Financing Round
March 27th 2025The £10 million (US$13 million) investment is part of a larger £58 million (US$75 million) Series A financing round to be used for the development of Maxion Therapeutics’ preclinical lead program for treating inflammatory diseases.